SWSijin Wu

Sijin Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sijin Wu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Yongliang Yang

    Center for Molecular Medicine, School of Life Science and Biotechnology, Dalian University of Technology, Dalian, People's Republic of China

    2 shared publications
  • Huaxi Xu

    Sanford-Burnham Medical Research Institute, La Jolla, California, USA

    1 shared publication
  • Huizhe (Howard) Luo

    Center for Molecular Medicine, School of Life Science and Biotechnology, Dalian University of Technology, Dalian, People's Republic of China

    1 shared publication
  • Jie Zhang

    Affiliations Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, Fujian, China, The Key Laboratory of Neural and Vascular Biology, Ministry of Education, Hebei Medical University, Shijiazhuang, Hebei, China, Institute of Neuroscience, Fujian Medical University, Fuzhou, Fujian, China

    1 shared publication
  • Jin Hu

    Institute of Neuroscience Xiamen University Xiamen 361005 China

    1 shared publication
  • Liyuan (Eric) Zhao

    Center for Molecular Medicine, School of Life Science and Biotechnology, Dalian University of Technology, Dalian, People's Republic of China

    1 shared publication

Latest Publications

  • Open Access

    Cancer Stem Cells Therapeutic Target Database: The First Comprehensive Database for Therapeutic Targets of Cancer Stem Cells

    by Xiaoqing Hu, Ye Cong, Huizhe (Howard) Luo, Sijin Wu, Liyuan (Eric) Zhao, Quentin Liu, Yongliang Yang

    Summary: Cancer stem cells (CSCs) are a subpopulation of tumor cells that have strong self-renewal capabilities and may contribute to the failure of conventional cancer therapies. Hence, therapeutics homing in on CSCs represent a novel and promising approach that may eradicate malignant tumors. However, the lack of information on validated targets of CSCs has greatly hindered the development of CSC-directed therapeutics. Herein, we describe the Cancer Stem Cells Therapeutic Target Database (CSCTT), the first online database to provide a rich bioinformatics resource for the display, search, and analysis of structure, function, and related annotation for therapeutic targets of cancer stem cells. CSCTT contains 135 proteins that are potential targets of CSCs, with validated experimental evidence manually curated from existing literatures. Proteins are carefully annotated with a detailed description of protein families, biological process, related diseases, and experimental evidences. In addition, CSCTT has compiled 213 documented therapeutic methods for cancer stem cells, including 118 small molecules and 20 biotherapy methods. The CSCTT may serve as a useful platform for the development of CSC-directed therapeutics against various malignant tumors. The CSCTT database is freely available to the public at http://www.csctt.org/.


  • Structural Bioinformatics‐Based Identification of EGFR Inhibitor Gefitinib as a Putative Lead Compound for BACE

    by Mingshan Niu, Jin Hu, Sijin Wu, Xiaoe Zhang, Huaxi Xu, Yunwu Zhang, Jie Zhang, Yongliang Yang

    β‐secretase (BACE‐1) is a potential target for the treatment of Alzheimer's disease (AD). Despite its potential, only few compounds targeting BACE have entered the clinical trials. Herein, we describe the identification of Gefitinib as a potential lead compound for BACE through an integrated approach of structural bioinformatics analysis, experimental assessment and computational analysis. In particular, we performed ELISA and western analysis to assess the effect of Gefitinib using N2a human APP695 cells. In addition, we investigated the binding mechanism of Gefitinib with BACE through molecular docking coupled with molecular dynamics simulations. The computational analyses revealed that hydrophobic contact is a major contributing factor to the binding of Gefitinib with BACE. The results obtained in the study have rendered Gefitinib as a putative lead compound for BACE. Further optimization studies are warranted to improve its potency and pharmacological properties against BACE for potential AD treatment.